These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 19098393

  • 21. [Genome research and anticancer chemotherapy].
    Hayashi I, Nishiyama M.
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1183-9. PubMed ID: 11579627
    [Abstract] [Full Text] [Related]

  • 22. [Current status and problems of tailor-made medicine in anticancer therapy].
    Miya T.
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):515-9. PubMed ID: 17431334
    [Abstract] [Full Text] [Related]

  • 23. [Target selectivity of anticancer drugs].
    Fattoruso SI, Di Lauro L, Conti F, Amodio A, Lopez M.
    Clin Ter; 2008 Apr; 159(3):189-206. PubMed ID: 18594750
    [Abstract] [Full Text] [Related]

  • 24. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
    Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA.
    Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
    [Abstract] [Full Text] [Related]

  • 25. Chemical approaches to the discovery and development of cancer therapies.
    Neidle S, Thurston DE.
    Nat Rev Cancer; 2005 Apr; 5(4):285-96. PubMed ID: 15803155
    [Abstract] [Full Text] [Related]

  • 26. Integrating genomics across drug discovery and development.
    Debouck C.
    Toxicol Lett; 2009 Apr 10; 186(1):9-12. PubMed ID: 18930125
    [Abstract] [Full Text] [Related]

  • 27. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM, Cassier PA, de Bono J.
    Cancer Discov; 2011 Aug 10; 1(3):207-12. PubMed ID: 22586572
    [Abstract] [Full Text] [Related]

  • 28. Facilitating patient-centered cancer research and a new era of drug discovery.
    Niederhuber JE.
    Oncologist; 2009 Apr 10; 14(4):311-2. PubMed ID: 19365096
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
    Chackalamannil S, Desai MC.
    Curr Opin Drug Discov Devel; 2009 Jul 10; 12(4):443-5. PubMed ID: 19562640
    [Abstract] [Full Text] [Related]

  • 31. [Development for and clinical trials of molecular targeting drugs].
    Takashima A, Fukuda H, Shibata T.
    Gan To Kagaku Ryoho; 2010 May 10; 37(5):822-7. PubMed ID: 20524257
    [No Abstract] [Full Text] [Related]

  • 32. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH.
    Cancer Chemother Pharmacol; 2009 Mar 10; 63(4):703-9. PubMed ID: 18615251
    [Abstract] [Full Text] [Related]

  • 33. The role of molecular imaging in drug discovery and development.
    Hargreaves RJ.
    Clin Pharmacol Ther; 2008 Feb 10; 83(2):349-53. PubMed ID: 18167503
    [Abstract] [Full Text] [Related]

  • 34. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
    Frijhoff AF, Conti CJ, Senderowicz AM.
    Mol Carcinog; 2004 Apr 10; 39(4):183-94. PubMed ID: 15057870
    [Abstract] [Full Text] [Related]

  • 35. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.
    Picker A, Jackson DB.
    Expert Rev Mol Diagn; 2011 Jul 10; 11(6):567-77. PubMed ID: 21745011
    [Abstract] [Full Text] [Related]

  • 36. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
    Wang H, Han H, Mousses S, Von Hoff DD.
    Semin Oncol; 2006 Aug 10; 33(4):513-20. PubMed ID: 16890805
    [Abstract] [Full Text] [Related]

  • 37. Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics.
    Kinsella TJ.
    Semin Oncol; 2009 Apr 10; 36(2 Suppl 1):S42-51. PubMed ID: 19393835
    [Abstract] [Full Text] [Related]

  • 38. Oncology drug discovery: planning a turnaround.
    Toniatti C, Jones P, Graham H, Pagliara B, Draetta G.
    Cancer Discov; 2014 Apr 10; 4(4):397-404. PubMed ID: 24706659
    [Abstract] [Full Text] [Related]

  • 39. [Cancer chemotherapy; past, present and future--from the aspect of fundamental studies].
    Tukagoshi S.
    Gan To Kagaku Ryoho; 2003 Oct 10; 30(10):1398-403. PubMed ID: 14584271
    [Abstract] [Full Text] [Related]

  • 40. Drug target interaction of tubulin-binding drugs in cancer therapy.
    Sengupta S, Thomas SA.
    Expert Rev Anticancer Ther; 2006 Oct 10; 6(10):1433-47. PubMed ID: 17069528
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.